In this article by Nigel Rawson & John Adams, readers learn that with national pharmacare, Canada still faces serious barriers in approval, reimbursement, and government plan listings. The commentary warns that multiple gatekeeper steps delay access to innovative medicines. It argues that without simplifying these layers, reform could reduce patient choice. The authors also raise concerns that restricting drug lists and relying too heavily on cost pressure may worsen outcomes rather than improve them.